Casdin Capital SLDB Position
Exited7-Fund ConvergenceCasdin Capital exited their position in Solid Biosciences Inc. (SLDB) in Q2 2025, after holding the stock for 2 quarters.
The position was first reported in Q1 2025 and has been tracked across 2 quarterly 13F filings.
SLDB is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout in 182 days (Oct 15, 2026), making the timing of Casdin's position particularly relevant.
Short interest stands at 11.3% of float with 5.7 days to cover, indicating significant bearish positioning against the stock.
About Solid Biosciences Inc.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Full company profile →Short Interest
11.3%
5.7 days to cover
Casdin Capital SLDB Position History
Frequently Asked Questions
Does Casdin Capital own SLDB?
No. Casdin Capital exited their position in Solid Biosciences Inc. (SLDB) in Q2 2025. They previously held the stock for 2 quarters.
How many hedge funds own SLDB?
7 specialist biotech hedge funds currently hold SLDB, including Perceptive Advisors, RA Capital Management, Deerfield Management and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Casdin Capital first buy SLDB?
Casdin Capital's position in SLDB was first reported in Q1 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Casdin Capital's SLDB position increasing or decreasing?
Casdin Capital completely exited their SLDB position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
SLDBCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Casdin CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →